Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial

P Pfeiffer; M. Yilmaz; S. Moller; D. Zitnjak; L. Maltha; M Krogh; S Winther; L Petersen; Finn Hejlesen; K. Thomsen; C Qvortrup

doi:10.1093/annonc/mdz154.013

Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial

P Pfeiffer, M. Yilmaz, S. Moller, D. Zitnjak, L. Maltha, M Krogh, S Winther, L Petersen, Finn Hejlesen, K. Thomsen, C Qvortrup

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	mdz154.013
Journal	Annals of Oncology
Volume	30
Issue number	Suppl. 4
Pages (from-to)	iv130-iv131
Number of pages	2
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdz154.013
Publication status	Published - 2019
Event	ESMO World Congress on Gastrointestinal Cancer 2019 - Barcelona, Spain Duration: 3 Jul 2019 → 6 Jul 2019 Conference number: 21 https://www.esmo.org/Conferences/ESMO-World-GI-2019

Conference

Conference	ESMO World Congress on Gastrointestinal Cancer 2019
Number	21
Country/Territory	Spain
City	Barcelona
Period	03/07/2019 → 06/07/2019
Internet address	https://www.esmo.org/Conferences/ESMO-World-GI-2019

Access to Document

10.1093/annonc/mdz154.013

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Pfeiffer, P., Yilmaz, M., Moller, S., Zitnjak, D., Maltha, L., Krogh, M., Winther, S., Petersen, L., Hejlesen, F., Thomsen, K., & Qvortrup, C. (2019). Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial. Annals of Oncology, 30(Suppl. 4), iv130-iv131. Article mdz154.013. https://doi.org/10.1093/annonc/mdz154.013

@article{27c6dfb24b19407d8475622f2dbb22c8,

title = "Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial",

author = "P Pfeiffer and M. Yilmaz and S. Moller and D. Zitnjak and L. Maltha and M Krogh and S Winther and L Petersen and Finn Hejlesen and K. Thomsen and C Qvortrup",

year = "2019",

doi = "10.1093/annonc/mdz154.013",

language = "English",

volume = "30",

pages = "iv130--iv131",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Suppl. 4",

note = "ESMO World Congress on Gastrointestinal Cancer 2019<br/>, ESMO19 ; Conference date: 03-07-2019 Through 06-07-2019",

url = "https://www.esmo.org/Conferences/ESMO-World-GI-2019",

}

Pfeiffer, P, Yilmaz, M, Moller, S, Zitnjak, D, Maltha, L, Krogh, M, Winther, S, Petersen, L, Hejlesen, F, Thomsen, K & Qvortrup, C 2019, 'Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial', Annals of Oncology, vol. 30, no. Suppl. 4, mdz154.013, pp. iv130-iv131. https://doi.org/10.1093/annonc/mdz154.013

Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial. / Pfeiffer, P; Yilmaz, M.; Moller, S. et al.
In: Annals of Oncology, Vol. 30, No. Suppl. 4, mdz154.013, 2019, p. iv130-iv131.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer

T2 - ESMO World Congress on Gastrointestinal Cancer 2019<br/>

AU - Pfeiffer, P

AU - Yilmaz, M.

AU - Moller, S.

AU - Zitnjak, D.

AU - Maltha, L.

AU - Krogh, M

AU - Winther, S

AU - Petersen, L

AU - Hejlesen, Finn

AU - Thomsen, K.

AU - Qvortrup, C

N1 - Conference code: 21

PY - 2019

Y1 - 2019

U2 - 10.1093/annonc/mdz154.013

DO - 10.1093/annonc/mdz154.013

M3 - Conference abstract in journal

SN - 0923-7534

VL - 30

SP - iv130-iv131

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 4

M1 - mdz154.013

Y2 - 3 July 2019 through 6 July 2019

ER -